Adage Capital Partners GP L.L.C. Has $10.78 Million Stock Holdings in ProQR Therapeutics N.V. $PRQR

Key Points

• Adage Capital Partners GP L.L.C. reduced its stake in ProQR Therapeutics by 15.6%, selling over 1.5 million shares, and now holds approximately 7.70% of the company.
• In contrast, Northern Trust Corp significantly increased its holdings in ProQR by 2,550.1%, now owning over 417,000 shares.
• ProQR Therapeutics reported a net income of ($0.14) per share for the quarter, falling short of analysts' expectations, alongside a negative net margin of 238.52%.

Adage Capital Partners GP L.L.C. cut its stake in shares of ProQR Therapeutics N.V. (NASDAQ:PRQR - Free Report) by 15.6% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 8,102,098 shares of the biopharmaceutical company's stock after selling 1,500,182 shares during the quarter. Adage Capital Partners GP L.L.C. owned approximately 7.70% of ProQR Therapeutics worth $10,776,000 as of its most recent SEC filing.

Several other institutional investors also recently made changes to their positions in PRQR. Jane Street Group LLC bought a new position in shares of ProQR Therapeutics during the fourth quarter valued at approximately $30,000. Alpine Global Management LLC bought a new position in shares of ProQR Therapeutics during the fourth quarter valued at approximately $39,000. Vontobel Holding Ltd. bought a new position in shares of ProQR Therapeutics during the first quarter valued at approximately $48,000. OneDigital Investment Advisors LLC grew its holdings in ProQR Therapeutics by 45.5% in the 1st quarter. OneDigital Investment Advisors LLC now owns 40,000 shares of the biopharmaceutical company's stock worth $53,000 after buying an additional 12,500 shares in the last quarter. Finally, Persistent Asset Partners Ltd bought a new position in ProQR Therapeutics in the 1st quarter worth approximately $64,000. 32.65% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of equities analysts recently issued reports on PRQR shares. Cantor Fitzgerald reissued an "overweight" rating and issued a $8.00 price objective on shares of ProQR Therapeutics in a report on Friday, June 27th. Chardan Capital reissued a "buy" rating and issued a $4.00 price objective on shares of ProQR Therapeutics in a report on Friday, August 8th. JMP Securities reissued a "market outperform" rating and issued a $8.00 price objective on shares of ProQR Therapeutics in a report on Friday, June 27th. Finally, Evercore ISI reissued an "outperform" rating on shares of ProQR Therapeutics in a report on Friday, July 11th. One equities research analyst has rated the stock with a Strong Buy rating and seven have given a Buy rating to the company. According to data from MarketBeat.com, the company has an average rating of "Buy" and an average price target of $8.00.

ProQR Therapeutics Price Performance

Shares of NASDAQ:PRQR remained flat at $2.19 on Friday. The stock had a trading volume of 472,345 shares, compared to its average volume of 346,714. ProQR Therapeutics N.V. has a one year low of $1.07 and a one year high of $4.62. The firm has a fifty day simple moving average of $2.21 and a 200 day simple moving average of $1.86. The stock has a market cap of $230.41 million, a PE ratio of -4.76 and a beta of 0.36.

ProQR Therapeutics (NASDAQ:PRQR - Get Free Report) last announced its quarterly earnings data on Thursday, August 7th. The biopharmaceutical company reported ($0.14) EPS for the quarter, missing analysts' consensus estimates of ($0.08) by ($0.06). ProQR Therapeutics had a negative net margin of 238.52% and a negative return on equity of 61.25%. The company had revenue of $4.33 million for the quarter, compared to analyst estimates of $5.01 million. As a group, research analysts forecast that ProQR Therapeutics N.V. will post -0.31 earnings per share for the current fiscal year.

About ProQR Therapeutics

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1).